Key result
Beta-blockers and ICDs remain primary ARVC therapies to control arrhythmias and prevent SCD.
Why the study?
Arrhythmogenic right ventricular cardiomyopathy is associated with a high risk of sudden cardiac death, requiring an updated summary of current knowledge on diagnostic assessment, risk stratification, and treatment.
This review summarizes current evidence and guideline recommendations for the diagnosis, risk stratification, and treatment of ARVC, emphasizing the role of risk calculators in guiding primary prophylactic defibrillator implantation.
No takes yet. Share an insight, caveat, or question.
Current ARVC management with beta-blockers and ICDs remains appropriate; leaves open prospective validation of risk calculators.
Kreimer et al. (2025) conducted a review in Arrhythmogenic right ventricular cardiomyopathy (ARVC). Diagnosis, risk stratification, and treatment strategies was evaluated. Arrhythmogenic right ventricular cardiomyopathy, with a prevalence of 1:2000 to 1:5000, is managed using beta-blockers for arrhythmias and implantable defibrillators to prevent sudden cardiac death.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: